Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer

The leading cause of death from malignant tumors worldwide is lung cancer. Before the development of molecularly targeted therapy, chemotherapy with platinum-based doublets was considered as the standard first-line treatment in advanced non-small cell lung cancer (NSCLC) patients. The introduction o...

Full description

Bibliographic Details
Main Authors:	Yung-Hung Luo, Yu-Chin Lee, Jacqueline Whang-Peng, Yuh-Min Chen
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-09-01
Series:	Journal of Cancer Research and Practice
Subjects:	gefitinib non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor
Online Access:	http://www.sciencedirect.com/science/article/pii/S2311300616300763

Similar Items

Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells
by: Haiying LI, et al.
Published: (2016-01-01)

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
by: Ping Chen, et al.
Published: (2019-06-01)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study
by: Fang YH, et al.
Published: (2019-09-01)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
by: Jung Hee Cho, et al.
Published: (2022-04-01)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
by: Sami Morin-Ben Abdallah, et al.
Published: (2017-05-01)

Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+
by: Viola Sacchi
Published: (2011-06-01)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
by: Yuan Ying, et al.
Published: (2012-11-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

Not COVID-19, Don’t Overlook Pneumocystis in Patients on Gefitinib!
by: Jérémy Barben, et al.
Published: (2021-02-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
by: Ming-Ju Tsai, et al.
Published: (2018-11-01)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
by: Melissa Bersanelli, et al.
Published: (2014-09-01)

Effect and Mechanism of Gefitinib Inhibition on Non-small Cell Lung Cancer  Radiosensitivity of HCC827 and H358 Cell Lines
by: Ziye GAO, et al.
Published: (2012-06-01)

Mucocutaneous side effects of gefitinib
by: Ruhaila Thekkath, et al.
Published: (2021-01-01)

Aspartames Alter Pharmacokinetics Parameters of Erlotinib and Gefitinib and Elevate Liver Enzymes in Wistar Rats
by: Hajer AlRasheed, et al.
Published: (2022-11-01)

Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung A Case Report
by: Francesca Aroldi, et al.
Published: (2014-07-01)

The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
by: C.L. Watkins, et al.
Published: (2010-09-01)

Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis
by: Hironori Uruga, et al.
Published: (2018-08-01)

The comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor receptor
by: V V Ryazhenov
Published: (2017-01-01)

Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats
by: Aliyah Almomen, et al.
Published: (2020-09-01)

Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib  in Patients with Non-small Cell Lung Cancer
by: Fei MA, et al.
Published: (2011-08-01)

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells
by: Yaya Yu, et al.
Published: (2023-08-01)

Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report
by: Genovefa Polychronidou, et al.
Published: (2013-03-01)

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
by: Michihito Miyagi, et al.
Published: (2022-12-01)

Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
by: Prashant Sakharkar, et al.
Published: (2024-03-01)

Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study
by: Qian J, et al.
Published: (2020-05-01)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
by: Guo-Hao Xia, et al.
Published: (2014-12-01)

Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer
by: Jianjie LI, et al.
Published: (2012-05-01)

How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01)

Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation
by: Yuhong Jiang, et al.
Published: (2021-04-01)

FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer
by: Cuilan Sun, et al.
Published: (2020-08-01)

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01)

M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR
by: Fengqi Xiao, et al.
Published: (2020-11-01)

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
by: Soomin Ahn, et al.
Published: (2016-07-01)

A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations (JMTO LC12‐01)
by: Kazuhiro Asami, et al.
Published: (2022-06-01)

The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis
by: Ainur F. Nasretdinov, et al.
Published: (2022-11-01)

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry studyResearch in context
by: Rolof G.P. Gijtenbeek, et al.
Published: (2023-04-01)

Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway
by: Shu-yi Chen, et al.
Published: (2021-01-01)